Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.

Díaz-Cruz ES, Furth PA.

Cancer Res. 2010 May 15;70(10):3965-74. doi: 10.1158/0008-5472.CAN-09-3450.

2.

Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.

Dabydeen SA, Kang K, Díaz-Cruz ES, Alamri A, Axelrod ML, Bouker KB, Al-Kharboosh R, Clarke R, Hennighausen L, Furth PA.

Carcinogenesis. 2015 Jan;36(1):122-32. doi: 10.1093/carcin/bgu237. Epub 2014 Nov 23.

3.

Biological and genetic properties of the p53 null preneoplastic mammary epithelium.

Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J, Allred DC, McCarthy M, Ullrich RL.

FASEB J. 2002 Jun;16(8):881-3. Epub 2002 Apr 10.

PMID:
11967232
4.

Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.

Blanco-Aparicio C, Cañamero M, Cecilia Y, Pequeño B, Renner O, Ferrer I, Carnero A.

PLoS One. 2010 Feb 19;5(2):e9305. doi: 10.1371/journal.pone.0009305.

5.

Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice.

Ewan KB, Oketch-Rabah HA, Ravani SA, Shyamala G, Moses HL, Barcellos-Hoff MH.

Am J Pathol. 2005 Aug;167(2):409-17.

6.

Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice.

Yan H, Blackburn AC, McLary SC, Tao L, Roberts AL, Xavier EA, Dickinson ES, Seo JH, Arenas RB, Otis CN, Cao QJ, Lawlor RG, Osborne BA, Kittrell FS, Medina D, Jerry DJ.

Am J Pathol. 2010 Mar;176(3):1421-32. doi: 10.2353/ajpath.2010.090438. Epub 2010 Jan 28.

7.

Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice.

Cheung AM, Elia A, Tsao MS, Done S, Wagner KU, Hennighausen L, Hakem R, Mak TW.

Cancer Res. 2004 Mar 15;64(6):1959-65.

8.
9.

P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis.

Fuchs-Young R, Shirley SH, Lambertz I, Colby JK, Tian J, Johnston D, Gimenez-Conti IB, Donehower LA, Conti CJ, Hursting SD.

Breast Cancer Res Treat. 2011 Nov;130(2):399-408. doi: 10.1007/s10549-010-1308-y. Epub 2010 Dec 30.

10.

A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha.

Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS.

Cancer Res. 1999 Apr 15;59(8):1869-76.

11.

Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.

Jerry DJ, Ozbun MA, Kittrell FS, Lane DP, Medina D, Butel JS.

Cancer Res. 1993 Jul 15;53(14):3374-81.

12.

Prepubertal physical activity up-regulates estrogen receptor beta, BRCA1 and p53 mRNA expression in the rat mammary gland.

Wang M, Yu B, Westerlind K, Strange R, Khan G, Patil D, Boeneman K, Hilakivi-Clarke L.

Breast Cancer Res Treat. 2009 May;115(1):213-20. doi: 10.1007/s10549-008-0062-x. Epub 2008 May 31.

13.

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer.

Johnstone CN, Smith YE, Cao Y, Burrows AD, Cross RS, Ling X, Redvers RP, Doherty JP, Eckhardt BL, Natoli AL, Restall CM, Lucas E, Pearson HB, Deb S, Britt KL, Rizzitelli A, Li J, Harmey JH, Pouliot N, Anderson RL.

Dis Model Mech. 2015 Mar;8(3):237-51. doi: 10.1242/dmm.017830. Epub 2015 Jan 29.

14.

The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice.

Mazumdar A, Medina D, Kittrell FS, Zhang Y, Hill JL, Edwards DE, Bissonnette RP, Brown PH.

Cancer Prev Res (Phila). 2012 Oct;5(10):1195-202. doi: 10.1158/1940-6207.CAPR-11-0524. Epub 2012 Aug 27.

15.

Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland.

Smith AP, Henze M, Lee JA, Osborn KG, Keck JM, Tedesco D, Bortner DM, Rosenberg MP, Reed SI.

Oncogene. 2006 Nov 23;25(55):7245-59. Epub 2006 Jun 5.

PMID:
16751806
16.
17.

Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice.

Tilli MT, Reiter R, Oh AS, Henke RT, McDonnell K, Gallicano GI, Furth PA, Riegel AT.

Mol Endocrinol. 2005 Mar;19(3):644-56. Epub 2004 Nov 18.

PMID:
15550471
18.

Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice.

Dunphy KA, Blackburn AC, Yan H, O'Connell LR, Jerry DJ.

Breast Cancer Res. 2008;10(3):R43. doi: 10.1186/bcr2094. Epub 2008 May 12.

19.

Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.

Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, Parrish A, Rosen EM, Furth PA.

Oncogene. 2008 Jan 31;27(6):794-802. Epub 2007 Jul 23.

20.

Supplemental Content

Support Center